At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
CVN058 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of CVN058 on Mismatch Negativity in Subjects With Stable Schizophrenia
In Brief
A Phase 1 clinical trial evaluating CVN058 and Placebo comparator for Schizophrenia. Completed, enrolled 22 participants across 3 sites.
Detailed Summary
This is a phase 1, double-blind, placebo-controlled, 3 period cross-over study to evaluate CVN058 target engagement by measuring auditory evoked potential mismatch negativity (MMN) downstream to 5-hydroxytryptamine receptor 3 (5-HT3) as a pharmacodynamic (PD) marker.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedSep 13, 2018
Enrollment StartNov 9, 2018
Primary CompletionMar 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.8 years ago
Interventions
CVN058drug
CVN058 will be given at two doses, a low does and a high dose
Placebo comparatorother
inactive placebo